Blood flow and oxygen extraction fraction — a measure of how well oxygen is used by tissues — in the…
Vanda Pinto, PhD
​​Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Vanda Pinto, PhD
Precision BioSciences and Novartis are teaming up to develop and commercialize a custom gene therapy as a potential treatment approach…
Naproxcinod, an investigational therapy being developed by Fera Pharmaceuticals as a treatment for sickle cell disease (SCD), has…
Imara has completed patient enrollment for its Phase 2b Ardent clinical trial, which is testing the safety and efficacy…